eureKARE news & blog

eureKARE seeks disruptive synthetic biology solutions to tackle environmental and sustainability challenges
03Jul

eureKARE seeks disruptive synthetic biology solutions to tackle environmental and sustainability challenges

In collaboration with the European project SYNBEE, which strives to enhance entrepreneurship in synthetic biology across Europe, we are calling on researchers and entrepreneurs with disruptive synthetic biology solutions that address our planet’s most pressing environmental and sustainability challenges.

Synthetic biology – the cross-sector tool that’s pushing the boundaries of innovation
30May

Synthetic biology – the cross-sector tool that’s pushing the boundaries of innovation

While many big companies believe science is key to continue innovating and expanding (as is exemplified by substantial R&D budgets), I am convinced that SynBio tools have the potential to boost all areas of innovation.

eureKING, the first European SPAC in healthcare dedicated tobiomanufacturing, announces the signature of a put option for thepotential acquisition of Skyepharma to build a new European bio-CDMO leader
30May

eureKING, the first European SPAC in healthcare dedicated tobiomanufacturing, announces the signature of a put option for thepotential acquisition of Skyepharma to build a new European bio-CDMO leader

The proposed transaction would represent the first cornerstone of eureKING’s project to pursue bolt-on acquisitions to add innovative companies from the fast growing biotherapies CDMO segment to its platform to create a bio-CDMO leader and which could result in additional transactions. These transactions may be announced before the completion of the proposed transaction.

eureKING, the first European SPAC in healthcare dedicated to biomanufacturing, announces its intention to combine with Skyepharma to build a new European bio-CDMO leader
16May

eureKING, the first European SPAC in healthcare dedicated to biomanufacturing, announces its intention to combine with Skyepharma to build a new European bio-CDMO leader

eureKING has a clear and identified roadmap to bolster Skyepharma’s technology platform to consolidate the highly fragmented European market in biomanufacturing capacity, such as state-of-the-art facilities to manufacture cell and gene therapies in Europe.

eureKARE wins EU grant to lead SYNBEE project
17Mar

eureKARE wins EU grant to lead SYNBEE project

The European project will enhance the commercial potential of one of today’s most disruptive fields

eureKARE co-founds EonBio to revolutionize drug discovery with pioneering cell-free technology on a chip
22Feb

eureKARE co-founds EonBio to revolutionize drug discovery with pioneering cell-free technology on a chip

eureKARE announces EonBio as the second company to be supported by its Belgium biomedical start-up studio

eureKARE appoints Anne Lauvergeon as a new Board member
08Feb

eureKARE appoints Anne Lauvergeon as a new Board member

Ms. Lauvergeon brings an extensive background in the management of large energy corporations (most notably as CEO of Areva), finance, and government.

eureKARE welcomes Dirac Biosciences as first company into its biomedical start-up studio
01Feb

eureKARE welcomes Dirac Biosciences as first company into its biomedical start-up studio

Innovative gene circuit technology has the potential to detect and treat cancerous and other diseased cells​

Monaco: a hotspot for untapped SynBio innovation
06Dec

Monaco: a hotspot for untapped SynBio innovation

Authored by eureKARE: Alexandre Mouradian (Chairman, Co-Founder and CEO)

eureKARE co-leads EUR 5 million seed investment in Biomemory which is advancing cutting-edge DNA-based data storage solutions
28Nov

eureKARE co-leads EUR 5 million seed investment in Biomemory which is advancing cutting-edge DNA-based data storage solutions

Biomemory, founded in 2021, is positioned at the crossroads of Biotechnology and IT and is a key player in the DNA data storage space. Its ambition is to help meet the climate challenge posed by data centers.

eureKARE launches innovation-driven start-up studio in Monaco to apply synthetic biology in tackling critical environmental challenges
15Nov

eureKARE launches innovation-driven start-up studio in Monaco to apply synthetic biology in tackling critical environmental challenges

This expands eureKARE’s synthetic biology studio network – each with a different theme – in Europe’s innovation hotspots. The Monaco studio will be the network’s hub for climate change-focused innovation.

Synthetic biology: the answer to climate change?
27Oct

Synthetic biology: the answer to climate change?

When it comes to innovation in synthetic biology (or “SynBio”), we’re seeing Europe punch above its weight but there remains a disconnect in seeing this translate into commercial value and investment, falling behind other major players, namely the US.

1 2 3 4

Luxembourg | France | Belgium

Subscribe to our news to keep in touch

Luxembourg | France | Belgium